Symposium: R21/Matrix-M: a high-impact malaria vaccine
When: Monday 22 April 2024, 13:30-15:00 (CAT)
Where: Kigali Convention Centre, Room AD10
Organiser: University of Oxford (UK)
The session aims to inform about the R21/Matrix-M malaria vaccine progress, data, and plans. During this session, the safety, immunogenicity, and efficacy data from the phase IIb and phase III trials of R21/Matrix-M will be presented as well as other trials assessing the impact of co-administration with Expanded Programme on Immunisation (EPI) vaccines and administration in HIV-positive children. The public health impact and cost-effectiveness across a wide range of transmission settings and data on the acceptability of the vaccine will also be presented. The manufacturing capacity, vaccine implementation plans, and where will be discussed, including the phase IV study design.
EDCTP project(s) highlighted
Agenda
Chairs:
- Richard Idro, Makerere University and Mulago Hospital (Uganda)
- Kwaku Poku Asante, Kintampo Health Research Centre (Ghana)
R21/Matrix-M: a high impact malaria vaccine
Mehreen S. Datoo, University of Oxford (UK)
Duration of protective efficacy of R21/Matrix-M
Emma Beaumont, London School of Hygiene & Tropical Medicine (UK)
Efficacy and immunogenicity of R21/Matrix-M over four malaria seasons in children in Burkina Faso: a phase IIb randomized controlled trial
Hamtandi M. Natama, Unité de Recherche Clinique de Nanoro, Institut de Recherche en Sciences de la Santé (Burkina Faso)
Modelling the Public Health Impact and Cost-Effectiveness of R21/Matrix-M Vaccine in Sub-Saharan Africa
Peter Winskill, MRC Centre for Global Infectious Disease Analysis, Imperial College (UK)
Acceptability of the R21 malaria vaccine alongside existing malaria interventions in Mali
Jane Grant, London School of Hygiene & Tropical Medicine (UK)
R21/Matrix-M: manufacturing capacity, vaccine implementation plans and phase 4 study design
Sandesh Bharati, Serum Institute of India Private Limited (India)
Further ongoing trials of R21/Matrix-M
Yahia Dicko, Malaria Research and Training Centre, University of Sciences, Techniques, and Technologies of Bamako (Mali) and Fernando Ramos Lopez, University of Oxford (UK) and University of Malaga (Spain)
Where next with R21/Matrix-M?
Adrian V.S. Hill, University of Oxford (UK)